Expiration Date: December 21, 2016
Media: Print with online posttest, evaluation, and request for credit
OverviewThis activity is designed to inform physicians about the latest treatment advances in soft-tissue sarcomas (STS), including approved and investigational management strategies.
Instructions For This Activity & Receiving Credit
Target AudienceThis activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat patients with STS. Surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the management of STS are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- Describe the shared-care model and its application to treatment of patients with STS
- Explain the significance of recent and upcoming studies in STS management
- Discuss the appropriate uses of combination therapy for STS
- Describe the primary principle regarding sequencing therapy for STS
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
George D. Demetri, MD
Professor of Medicine, Harvard Medical School Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics Dana-Farber Cancer Institute
Disclosure: Consultant, consulting fees: Bayer, Novartis, Pfizer, Lilly, EMD-Serono, Sanofi Oncology, Janssen Oncology, PharmaMar, GlaxoSmithKline, Daiichi- Sankyo, Ariad, AstraZeneca, WIRB-Copernicus Group, ZIOPHARM Oncology, and Polaris; Research support to Dana-Farber for specific clinical trial agreements in their sarcoma unit: Bayer, Novartis, EMD-Serono, Sanofi Oncology, Janssen Oncology, and GlaxoSmithKline; Patent licensed to Novartis from Dana-Farber with royalty paid to Dana-Farber; Consultant, Scientific Advisory Board consulting fees, Equity (minor stake, nonpublic): Kolltan Pharmaceuticals; Member, Board of Directors, Member, Scientific Advisory Board Fees and Equity (minor stake, nonpublic): Blueprint Medicines; Consultant, Scientific Advisory Board consulting fees/Equity (minor stake, nonpublic): G1 Therapeutics and Caris Life Sciences; Consultant, Scientific Advisory Board consulting fees (>$10k, <$20k) and Equity (minor stake, nonpublic): Champions Oncology; Consultant, uncompensated, Equity (minor stake, nonpublic): Bessor Pharma
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded by Physicians' Education Resource®, LLC.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise